Physician profile
Garnet Foster King
NPI 1972780435
$969.10
in general payments reported to CMS, 2019-2025
14 companies · $19.27 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $219 · 2023: $46.23 · 2025: $19.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.70 | 2021-2022 | |
| Alkermes, INC. | $146.49 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $130.80 | 2021-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $104.86 | 2021-2022 | |
| Indivior INC. | $56.33 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $44.79 | 2021 | |
| Avanir Pharmaceuticals, INC. | $33.83 | 2021 | |
| Novo Nordisk INC | $20.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.41 | 2021 | |
| Noven Pharmaceuticals, INC. | $16.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.53 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.62 | 2021 | |
| Lundbeck LLC | $14.14 | 2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garnet King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.